Skip to content
Axe Capital logo Axe Capital Trading News

Is Oklo a Millionaire Maker, or Is the Hype Overdone?

2026-08-11 00:05 Steven Porrello The Motley Fool Positive Axe Cap view: Selective EquitiesEarningsTechnologyAISemiconductors OKLO

Axe Cap view

Oklo’s Nuclear Ambitions: Too Early to Bet Big

Oklo’s early milestones spark excitement but sky-high valuation and pre-commercial risks caution patience.

Oklo’s jump to first revenue and achieving criticality in its test reactor are noteworthy steps in the small nuclear reactor space. However, the company’s valuation at over 1,700 times sales feels disconnected from the reality on the ground. For South African investors scanning the JSE, this type of story is a cautionary tale rather than an actionable trade—our market remains focused on banks, energy majors, and consumer stocks with real earnings today. Unlike Oklo’s long runway, companies like Sasol face immediate earning challenges tied to oil prices and Rand volatility, giving a clearer read on value. Oklo’s promise depends heavily on commercialising unproven tech under regulatory uncertainty, and that makes it a speculative gamble. Rand investors watching USD/ZAR swings would do better to anchor decisions in local names or FX where fundamentals are clearer. The excitement around Oklo might be misplaced until more concrete cash flows show up, but if nuclear gains faster policy backing or Asia moves first on modular reactors, sentiment could shift sharply. this is just our opinion and not financial advice

How I would invest

Avoid Oklo for now given the extreme valuation and pre-commercial risks. More disciplined exposure lies in JSE counters like Sasol or MTN that have clearer operating and currency linkages.

What I would watch
  • OKLO
  • Sasol
  • USD/ZAR
What could go wrong
  • Oklo failing to commercialize reactors as planned
  • Sharp corrections in USD/ZAR impacting foreign investment flows
How strongly I feel

5/10

Oklo reported its first-ever quarterly revenue of $1.21 million and achieved first criticality on its Groves test reactor, causing the stock to surge 14%. While the company has $3 billion in liquidity and operates three promising businesses (small nuclear reactors, fuel fabrication/recycling, and isotopes), concerns remain about its pre-commercial status and extremely high valuation of over 1,700x sales. The company faces significant commercialization challenges before its ambitious growth projections can be validated.

Our take is based on reporting first published by The Motley Fool.

Read the original story